LIFDOTCPharmaceutical PreparationsFiscal year ends December 31

LFTD PARTNERS INC.

Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on Aug 14, 2026

$0.10+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $1.48M
P/E (TTM): –
Dividend yield: –

LFTD PARTNERS INC. income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Revenue	37	37	52	57	32	5.34	0	–	–	–	–	–	–	0.25	0.46	4.85
Cost of Revenue	24	25	32	36	16	3.41	0	–	–	–	–	–	–	0.28	0.19	2.51
Gross Profit	13	13	20	21	16	1.94	0	–	–	–	–	–	–	-0.03	0.27	2.34
Research & Development	–	–	0.02	0.02	–	–	–	–	–	–	–	–	–	–	–	–
Selling, General & Admin	–	–	–	–	–	0.13	0.06	0.01	0.07	0.08	0.15	0.31	0.24	0.83	0.21	2.47
General & Administrative	–	–	–	–	–	–	–	–	0.07	0.08	–	–	–	–	–	–
Advertising Expenses	1.99	1.16	0.95	0.66	0.34	0.12	0.01	–	–	–	–	–	–	–	–	–
Operating Expenses	12	14	17	11	8.16	3.46	1.26	–	–	–	–	–	–	1.22	0.21	–
Operating Income	0.91	-0.77	2.41	9.81	7.78	-1.52	-1.26	-0.18	–	–	–	–	–	-1.25	-0.21	-0.12
Interest Expense	–	–	0.11	0.12	0.14	0.07	0.03	0.04	0	–	–	–	0.00	0.15	0.02	0.06
Interest & Investment Income	0.09	0.15	0.04	0.01	0.00	0.01	0.03	0	–	0	0.06	0.04	–	–	–	–
Income from Equity Investments	–	–	–	0	-0.20	0.00	0	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	-25	-1.61	0.35	0.18	-0.61	-0.02	0.03	-0.04	–	–	–	–	–	–	–	–
Asset Impairment Charges	23	0	0	0	0.39	–	–	–	–	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	0	-0.05	0	-0.19	0.00	0	0	–	–	–	–	–	–	–	–	–
Legal Settlements	0	0.00	0	0	-0.10	-0.10	–	–	–	–	–	–	–	–	–	–
Pretax Income	-24	-2.38	2.76	9.99	7.17	-1.53	0	-0.22	–	–	–	–	–	–	-4.30	-0.19
Income Tax Expense	0.43	-0.52	0.60	-2.80	1.37	0	-1.24	0	0	0	0	0	0	–	0.00	0.01
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	–	-1.18	-5.40	-0.33	-1.03	-0.23	–
Income from Discontinued Operations	–	–	–	–	–	–	–	–	–	–	0	0.07	0.18	-1.34	4.07	–
Net Income incl. Noncontrolling Interests	–	–	–	7.20	5.80	-1.53	–	-0.22	-0.08	-0.18	-1.18	-5.32	4.47	-2.36	-4.30	-0.20
Minority Interest in Earnings	–	–	–	–	0.08	0	0	–	–	–	–	–	–	–	–	–
Net Income	-25	-1.86	2.16	7.20	5.80	-1.53	-1.24	-0.22	-0.08	-0.18	-1.18	-5.32	4.47	–	–	–
Net Income to Common	-25	-1.87	2.14	–	–	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	-1.68	-0.13	0.15	0.51	0.50	-0.29	-0.48	-0.09	-0.03	-0.08	-0.52	-2.34	1.61	-0.86	-1.86	-0.09
EPS (Diluted)(per share)	-1.68	-0.13	0.13	0.45	0.43	-0.29	-0.48	-0.09	-0.03	-0.08	-0.52	-2.34	1.61	-0.86	-1.86	-0.09
Shares Outstanding (Basic, Weighted)(shares)	15	15	15	14	11	5.93	2.58	2.37	2.37	2.33	2.27	2.27	2.78	2.75	–	–
Shares Outstanding (Diluted, Weighted)(shares)	15	15	16	16	13	5.93	2.58	2.37	2.37	2.33	2.27	2.27	2.78	2.75	2.31	2.18
EBITDA	1.47	-0.25	2.84	10	7.87	-1.50	-1.26	–	–	–	–	–	–	-1.21	-0.16	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Mar 31, 2026

Profitability, TTM

Gross margin: 23.5%
Operating margin: -9.0%
Net margin: -77.7%
Return on equity, FY2025: -99.2%

Financial strength

Current ratio: 2.26
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 46.0%

Valuation

P/E ratio: –
Price to sales: 0.04
Price to book: 0.18
Dividend yield: –